Aura Biosciences Business Summary

Aura Biosciences, Inc. (AURA) is a clinical-stage biopharmaceutical company that generates value through the development and commercialization of its proprietary Virus-Like Drug Conjugate (VDC) platform. The company’s business model focuses on high-precision oncology therapies, primarily segmented into Ocular Oncology—where its lead candidate, belzupacap sarotalocan (bel-sar), is in Phase 3 trials for choroidal melanoma—and Urologic Oncology, targeting non-muscle invasive bladder cancer. While currently pre-revenue from product sales, Aura leverages strategic partnerships and licensing agreements to fund its pipeline of "molecular surgery" candidates designed to destroy cancer cells while preserving organ function. In the competitive landscape, Aura contends with players such as Immunocore, Amgen, and uniQure, positioning itself as a specialized leader in viral-vector-based targeting that offers superior precision and reduced off-target toxicity compared to traditional antibody-drug conjugates. Aura was founded in 2007 by CEO Elisabet de los Pinos, PhD, alongside co-founder J. John Schiller, PhD. Dr. de los Pinos brings extensive oncology expertise from her tenure at Eli Lilly and the Institute of Cancer Research. The executive leadership team includes Tony Gibney as Chief Financial and Business Officer, Dr. Jill Hopkins (formerly of Novartis and Roche-Genentech) as Chief Medical Officer and President of R&D, and Dr. Mark Plavsic (previously at Sanofi Genzyme) as Chief Technology Officer. Aura is backed by a robust roster of institutional investors, including Matrix Capital Management, Frazier Life Sciences, and Advent International. The Board of Directors, chaired by David Johnson, features prominent industry figures from Medicxi and Ysios Capital, reflecting a strong pedigree in global biopharmaceutical commercialization.